Skip to content
2000
Volume 16, Issue 2
  • ISSN: 1871-5303
  • E-ISSN: 2212-3873

Abstract

Immunoglobulin therapy represents a lifesaving intervention for many patients with primary immunodeficiency (PID). Antibody defects represent approximately half of the well-known PIDs requiring immunoglobulin replacement therapy. Following immunoglobulin therapy in PID patients, protection against serious upper and lower respiratory tract infections and pulmonary function improves which leads to an increase in the quality of life of these patients. Successful treatment of PID patients depends on the type of immunodeficiency, regular monitoring of the patient, comorbidities of the patient, and the availability of the products.

Loading

Article metrics loading...

/content/journals/emiddt/10.2174/1871530316666160724214418
2016-06-01
2024-12-26
Loading full text...

Full text loading...

/content/journals/emiddt/10.2174/1871530316666160724214418
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test